MedTrace Logo

Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke

NCT02258880 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-10-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of SUN13837 and to determine whether SUN13837 improves the physical performance, relative to placebo, following an acute stroke in adult subjects.

Conditions

Interventions

DRUG

SUN13837

DRUG

placebo

Sponsors & Collaborators

Principal Investigators

  • Ger Rikken, MD · Asubio Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States
  • Canada
  • Israel
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02258880 on ClinicalTrials.gov